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Functional characterization of the sigmaB-dependent
yabJ-spoVG operon in Staphylococcus aureus: role in methicillin
and glycopeptide resistance
Abstract
The alternative sigma factor sigma(B) of Staphylococcus aureus controls the expression of multiple
genes, including virulence determinants and global regulators; promotes capsule production; and
increases the resistance levels of methicillin-resistant S. aureus (MRSA) and
glycopeptide-intermediate-resistant S. aureus (GISA) strains. We show here that deletion of the
sigma(B)-controlled yabJ-spoVG operon, which codes for potential downstream regulators of sigma(B),
abolished capsule synthesis and reduced resistance in MRSA and GISA to the same extent that sigma(B)
inactivation did. Introduction of the yabJ-spoVG operon in trans restored the original phenotype. By
genetic manipulations, we show that SpoVG but not YabJ is required for complementation. We
therefore postulate that SpoVG is the major factor of the yabJ-spoVG operon required in S. aureus for
capsule formation and antibiotic resistance.
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The alternative sigma factor B of Staphylococcus aureus controls the expression of multiple genes, including
virulence determinants and global regulators; promotes capsule production; and increases the resistance levels
of methicillin-resistant S. aureus (MRSA) and glycopeptide-intermediate-resistant S. aureus (GISA) strains.
We show here that deletion of the B-controlled yabJ-spoVG operon, which codes for potential downstream
regulators of B, abolished capsule synthesis and reduced resistance in MRSA and GISA to the same extent
that B inactivation did. Introduction of the yabJ-spoVG operon in trans restored the original phenotype. By
genetic manipulations, we show that SpoVG but not YabJ is required for complementation. We therefore
postulate that SpoVG is the major factor of the yabJ-spoVG operon required in S. aureus for capsule formation
and antibiotic resistance.
A large set of virulence factors allows Staphylococcus aureus
to cause a wide spectrum of diseases, which range from super-
ficial to life-threatening infections (26). The production of the
virulence determinants is tightly controlled by a network of
global regulators, including the alternative transcription factor
B (for reviews, see references 8 and 30). Besides its role in the
general stress response (7, 12, 13, 19, 24, 25), B affects me-
thicillin and glycopeptide resistance (2, 28, 34, 39, 40), pigment
production (13, 21, 25, 28, 32), internalization into endothelial
cells (29), S. aureus-induced apoptosis (16), and capsule for-
mation (27) and modulates the expression of a variety of vir-
ulence factors and regulatory elements (for a review, see ref-
erence 3). Recent microarray analyses showed that B affects
the expression of a large number of genes/operons (3, 33).
However, a surprisingly large fraction of these genes/operons
are not preceded by an apparent B promoter (18), including
e.g., the cap operon, which codes for capsular polysaccharide
production (for a review, see reference 31), and fnbA, which
codes for fibronectin binding protein A. This indicates that
downstream-acting regulators mediating the effect of the alter-
native transcription factor B should exist. The way B exerts
its impact on the resistance to cell wall antibiotics and capsule
formation as well as the postulated B effectors remain unknown.
We recently showed that inactivation of the staphylococcal
B-controlled yabJ-spoVG operon, which codes for Bacillus
subtilis YabJ and SpoVG sequence homologs, significantly re-
duces the level of transcription of the cap operon and impedes
capsule formation in capsular polysaccharide-producing strain
Newman (27), suggesting that products of the yabJ-spoVG lo-
cus might serve as B effectors that modulate B-dependent
genes lacking an apparent B promoter.
In this study, we deleted the yabJ-spoVG operon and ana-
lyzed its effect on the resistance levels of methicillin-resistant S.
aureus (MRSA) and glycopeptide-intermediate-resistant S. au-
reus (GISA) strains. We present here data showing that the
deletion of the yabJ-spoVG operon decreases resistance in
MRSA and GISA and that SpoVG is the major effector mol-
ecule of the yabJ-spoVG locus with respect to resistance and
capsule formation.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. The bacterial strains and
plasmids used in this study are listed in Table 1. The bacteria were grown on
sheep blood agar or in Luria-Bertani (LB) broth (Difco Laboratories, Detroit,
MI) with shaking (180 rpm) at 37°C. When required, the media were supple-
mented with either 100 g ampicillin, 10 g erythromycin, 50 g kanamycin, or
10 g tetracycline per ml.
Molecular biological methods. General molecular biology techniques were
performed according to the standard protocols described by Sambrook et al. (37)
and Ausubel et al. (1).
Strain construction. To construct S. aureus yabJ-spoVG mutants, fragments
covering 0.8 kb of the yabJ upstream region (up-fragment) and 1.0 kb of the
spoVG downstream region (down-fragment) were amplified by PCR with primer
pairs oSTM49-oSTM50 and oSTM03-oSTM04 and S. aureus COL DNA as the
template (Tables 1 and 2). The products were digested with KpnI-BamHI and
PstI-HindIII, respectively, and cloned into plasmid pEC1 (6), with the up-frag-
ment preceding the erm(B) cassette and the down-fragment following the resis-
tance marker. The resulting plasmid, pSTM14, was digested with KpnI and
HindIII, and the insert was cloned into the suicide vector pBT (13), yielding
plasmid pSTM15, which was electroporated into RN4220 (23) (Fig. 1). Allelic
replacement mutants were selected with erythromycin and screened for the loss
of tetracycline resistance, resulting in strain SM133(RN4220 yabJ-spoVG::erm(B)),
which served as a donor for the transduction of the yabJ-spoVG deletion into S.
aureus strains of different genetic backgrounds (Table 1). S. aureus rsbUVW-
sigB mutants BS126 and BS128 were constructed by transducing the rsbUVW-
sigB::erm(B) mutation of strain IK184 (25) into strains NM143 (38) and COLn
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(20), respectively. The deletion of the yabJ-spoVG and the sigB operons was
confirmed by PCR and Southern analyses, and the absence of major rearrange-
ments after genetic manipulation of the strains was confirmed by whole-genome
SmaI pulsed-field gel electrophoresis.
Construction of reporter gene plasmids pSTM19, pSTM20, and pSTM21.
DNA fragments covering different parts of the yabJ-spoVG region were amplified by
PCR with primer pairs oSTM66-oSTM69 (for pSTM16), oSTM66-oSTM67 (for
pSTM17), and oSTM68-oSTM69 (for pSTM18) and with S. aureus COL DNA as
the template (Tables 1 and 2). The resulting PCR products were digested with
KpnI-NcoI and cloned into pSP-luc (Promega) upstream of the luciferase reporter
gene luc. The yabJ-spoVG regions fused to luc in the resulting plasmids were
excised with KpnI and XbaI and cloned into the Escherichia coli-S. aureus shuttle
plasmid pBus1 (36) to obtain plasmids pSTM19, pSTM20, and pSTM21, respec-
tively. The identities of the inserts were confirmed by sequencing.
Construction of complementation plasmids pSTM08, pSTM09, and pSTM10.
A DNA fragment covering yabJ-spoVG and the preceding B-dependent pro-
moter, PyabJ, was amplified by PCR with primer pair oSTM07-oSTM08 and S.
aureus COL DNA as the template (Tables 1 and 2). The resulting product was
digested with BamHI and KpnI and cloned into shuttle plasmid pBus1 (36),
yielding plasmid pSTM08. To mutagenize either yabJ or spoVG in pSTM08, the
TABLE 1. Strains and plasmids used in this study
Strain or
plasmid Relevant genotype; phenotype
a Reference or source
S. aureus
BB938 NCTC8325 GISA derivative; Ter 5
COL Clinical isolate, mec; Mcr Tcr 22
COLn Tcs derivative of COL; Mcr 20
IK183 COL rsbUVW-sigB::erm(B); Emr 25
IK184 Newman rsbUVW-sigB::erm(B); Emr 25
Newman Clinical isolate (ATCC 25904); CP-5 producer 11
NM143 Newman GISA derivative, in vitro-selected mutant; Ter 38
PG223 BB938 rsbUVW-sigB::erm(B); Emr 5
RN4220 NCTC8325-4 r m 23
BS126 NM143 rsbUVW-sigB::erm(B); Emr This study
BS128 COLn rsbUVW-sigB::erm(B); Emr This study
SM133 RN4220 yabJ-spoVG::erm(B); Emr This study
SM148 Newman yabJ-spoVG::erm(B); Emr This study
SM154 COL yabJ-spoVG::erm(B); Emr Tcr This study
SM159 BB938 yabJ-spoVG::erm(B); Emr This study
SM165 COLn yabJ-spoVG::erm(B); Emr This study
SM233 NM143 yabJ-spoVG::erm(B); Emr This study
E. coli
BL21(D3) F ompT gal dcm lon hsdSB (rB
 mB
) (DE3) Novagen
DH5 F 80d/lacZM15 recA1 Invitrogen
Plasmids
pBT 1.6-kb PCR fragment of the tet(L) gene of pHY300PLK into Alw26I-digested pBC SK()
(Stratagene); Tcr
13
pBus1 E. coli-S. aureus shuttle plasmid with multicloning site from pBluescript II SK (Stratagene) and the
rrnT14 terminator sequence from pLL2443; Tc
r
36
pEC1 pUC derivative containing the 1.45-kb ClaI erm(B) fragment of Tn551; Apr Emr 6
pET-28a() Expression vector; Kmr Novagen
pSP-luc Firefly luciferase casette vector; Apr Promega
pSTM08 pBus1 with a 2.1-kb PCR fragment covering yabJ, spoVG, and the preceding B-dependent
promoter PyabJ; Tc
r
This study
pSTM09 pBus1 with a 2.1-kb PCR hybrid, including the B-dependent promoter PyabJ, yabJ, and
spoVG1(Am); Tcr
This study
pSTM10 pBus1 with a 2.1-kb PCR hybrid, including the B-dependent promoter PyabJ, yabJ1(Am), and
spoVG; Tcr
This study
pSTM11 pBus1 with a 0.6-kb PCR fragment covering yabJ and the preceding B-dependent promoter PyabJ;
Tcr
27
pSTM13 pBus1 with a 0.5-kb PCR hybrid including the B-dependent promoter PyabJ fused to the spoVG
ORF; Tcr
27
pSTM14 pEC1 with 0.8- and 1.0-kb PCR fragments covering the yabJ-spoVG flanking regions; Emr Apr This study
pSTM15 pBT with a 3.3-kb KpnI-HindIII fragment of pSTM14 harboring the yabJ-spoVG flanking regions
and the erm(B) cassette replacing yabJ-spoVG; Emr Tcr
This study
pSTM16 pSP-luc with a 0.8-kb PCR fragment covering the region preceding the spoVG ORF up to the yabJ
promoter region fused to the reporter gene luc; Apr
This study
pSTM17 pSP-luc with a 0.4-kb PCR fragment covering the yabJ promoter region fused to the reporter gene
luc; Apr
This study
pSTM18 pSP-luc with a 0.4-kb PCR fragment covering the region preceding the spoVG ORF up to the 5
part of yabJ fused to the reporter gene luc; Apr
This study
pSTM19 pBus1 with a 0.8-kb KpnI-XbaI fragment of pSTM16 harboring the PyabJ-yabJ-luc
 fusion; Tcr This study
pSTM20 pBus1 with a 0.4-kb KpnI-XbaI fragment of pSTM17 harboring the yabJ promoter-luc fusion; Tcr This study
pSTM21 pBus1 with a 0.4-kb KpnI-XbaI fragment of pSTM18 harboring the region preceding the spoVG
ORF up to the 5 part of yabJ fused to the reporter gene luc; Tcr
This study
pSTM33 pET-28a() with 0.33-kb fragment covering spoVG; Kmr This study
a Abbreviations: Apr, ampicillin resistant; Emr, erythromycin resistant; Kmr, kanamycin resistant; Mcr, methicillin resistant; Tcr, tetracycline resistant; Ter, teicoplanin
resistant.
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following strategies were applied. For pSTM09 [PyabJ-yabJ-spoVG1(Am)], a mu-
tation was introduced into spoVG with primer pairs oSTM07-oSTM42 and
oSTM43-oSTM08 on pSTM08 to amplify PyabJ-yabJ, including the 5 part of
spoVG and the 3 part of spoVG, respectively. The resulting PCR products were
digested with BamHI-SacI and SacI-KpnI and cloned into pBus1, thereby intro-
ducing a frame shift into spoVG, resulting in an amber mutation at amino acid 26.
For pSTM10 [PyabJ-yabJ1(Am)-spoVG], which harbors a point mutation in yabJ,
primer pairs oSTM07-oSTM40 and oSTM41-oSTM08 were used together with
pSTM08 to amplify DNA fragments covering PyabJ, including the 5 part of yabJ
and the 3 part of yabJ followed by spoVG, respectively. The resulting products
were digested with BamHI-SacI and SacI-KpnI and cloned into pBus1, thereby
introducing a frame shift into yabJ, yielding in an amber mutation at amino acid
22. The identities of the inserts were confirmed by sequencing.
Luciferase assay. Luciferase activity was measured as described earlier (4) by
using the luciferase assay substrate and a Turner Designs TD-20/20 luminometer
(Promega).
Primer extension experiments. The transcriptional start points were mapped
by primer extension analysis, as described by Harraghy et al. (15). DNA frag-
ments were amplified by PCR with S. aureus COL DNA as the template. The
probes yabJ-pe and spoVG-pe were prepared by using the forward primers
yabJpe-F and spoVGpe-F, respectively, together with the 5-end-labeled reverse
primers yabJpe-R and spoVGpe-R, respectively. The oligonucleotides were 5
end labeled with [	-32P]ATP (4,500 Ci mmol1; ICN) and T4 polynucleotide
kinase (Biolabs).
Capsule determination. Capsular polysaccharide type 5 (CP-5) production was
determined by indirect immunofluorescence from cultures grown for 8 h in LB
broth, as described earlier (38), using mouse immunoglobulin M monoclonal
antibodies to CP-5 (17).
Susceptibility testing. Plates containing an antibiotic gradient were prepared
as described before (38). Cells of the strains to be tested were resuspended in
physiological NaCl solution to a density of a 0.5 McFarland standard and
swabbed onto the plate along the gradient. Growth was read after 24 h and 48 h
of incubation at 35°C. Teicoplanin and vancomycin MICs were determined by
using Etests, according to the manufacturer’s instructions (AB Biodisk, Solna,
Sweden). Oxacillin MICs were determined by broth microdilution, as recom-
mended by the Clinical and Laboratory Standards Institute (9), except that LB
broth instead of cation-adjusted Mueller-Hinton broth with 2% NaCl was used.
Population analysis profiles were established by plating appropriate dilutions
of an overnight culture on LB agar plates containing increasing concentrations of
oxacillin or teicoplanin. The numbers of CFU were determined after 48 h
of incubation at 35°C.
SpoVG-His6 expression and antibody preparation. For the construction of
SpoVG-His6-overexpressing plasmid pSTM33, a 0.33-kb DNA fragment cover-
ing the open reading frame (ORF) of spoVG was amplified by PCR with primer
pair oSTM05-oSTM06 and S. aureus Newman DNA as the template (Tables 1
and 2). The fragment was cloned into the expression vector pET28a() (Nova-
gen) by using the NdeI and XhoI restriction sites, such that the hexahistidine tag
was fused in frame to the C terminus of SpoVG. pSTM33 was electroporated
into E. coli DH5, and the insert was verified by sequencing and was finally
introduced into strain BL21(DE3) (Novagen) for overexpression. Cells were
grown in LB broth to an optical density at 600 nm of 0.5 and induced with 0.3
mM isopropyl-
-D-thiogalactopyranoside. After 3 h, cells were collected by cen-
trifugation and resuspended in 30 ml phosphate-buffered saline (pH 7.4) sup-
plemented with a complete EDTA-free protease inhibitor cocktail tablet
(Roche) and 0.1 mg ml1 DNase. The cells were disrupted (Cell Cracker;
EMBL, Heidelberg, Germany), and the debris was separated by centrifugation at
13,000  g for 10 min. Purification of the His-tagged protein was performed on
nickel-nitriloacetic acid columns, according to the recommendations of the man-
ufacturer (Qiagen, Basel, Switzerland). The protein sample was further purified
by analytical gel filtration on a Superdex 75 HR column on a Pharmacia Biotech
fast-performance liquid chromatography system. The correct molecular weight
of the purified protein was confirmed by nano-electrospray ionization mass
spectrometry and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
One milligram of the purified SpoVG-His6 was used to raise polyclonal chicken
antibodies (Davids Biotechnologie, Regensburg, Germany). The resulting crude
antiserum was purified against the immobilized SpoVG antigen.
Western blot analysis. Cytoplasmic protein extracts were obtained by lysing S.
aureus, grown in LB broth at 37°C for 5 h, in phosphate-buffered saline (pH 7.4)
TABLE 2. Primers used in this study
Primer Sequence (5–3)a Locationb or reference
yabJpe-F gcgggtaccTGCTAATATTTTAAATTTACC 548406–548426
yabJpe-R TATGGTCCAAGTGCTTCCG 548832–548850
spoVGpe-F gcgggtaccCAACAGTTGTGAATGGTATGGTTTATAC 548859–548886
spoVGpe-R GCATTGCAACGAACAAGCC 549379–549397
oSTM03 cgcctgcagATTATGATGATATGAAAATTATTG 27
oSTM04 gcgaagcttGACCAATAACAACATCTTCGCC 27
oSTM05 gggggctcaccatatgaaAGTGACAGATGTAAGAC 549256–549277
oSTM06 aaaatctcgagAGCTTCTTCTGAATCTTCTGATGTAGC 549529–549556
oSTM07 gaagggatccGATTTGGTAGGTAATCCATCGCTACTAAAC 548281–548310
oSTM08 gcgcggtaccCTAATTTCATTAATATCCTTTTCAGCTTGC 550378–550407
oSTM40 gcggagctcCGAATATGGTCCAAGTGCTTCC 548833–548854
oSTM41 gcggagctcCAGTTGTGAATGGTATGGTTTATAC 548862–548886
oSTM42 gcggagctcCATTCGTCCATCTGTTTGTATTTTTC 549281–549306
oSTM43 gcggagctcCACTCGTTTCCATTACATTAGATG 549311–549334
oSTM49 gcgggtaccGTTGAAAAGATGAGATATAAACGAAG 547954–547979
oSTM50 gcgggatccCTAAAACTCCTTTTATGAAAACTTAG 548774–548799
oSTM66 gcgggtaccTGCTAATATTTTAAATTTACC 548406–548426
oSTM67 gcgccatggTACTAAAACTCCTTTTATGAAAAC 548778–548801
oSTM68 gcgggtaccCAACAGTTGTGAATGGTATGGTTTATAC 548859–548886
oSTM69 gcgccatggAGTGAGCCCCCCTATAGTATATATC 549229–549253
a Lowercase letters represent nucleotide additions.
b Based on the sequence of strain COL (RefSeq accession no. NC_002951).
FIG. 1. Genetic organization of the S. aureus yabJ-spoVG locus.
Schematic representations of the yabJ-spoVG region of S. aureus COL
and its yabJ-spoVG mutant, strain SM154, are shown. ORFs, promot-
ers, and terminators are indicated. ORF notations and nucleotide (nt)
numbers correspond to those of the respective genomic regions of
strain COL (RefSeq accession no. NC_002951).
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containing 2 mM phenylmethylsulfonyl fluoride and 40 g each of lysostaphin,
lysozyme, DNase, and RNase per ml. Protein fractions (50 g/lane) were sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted onto
nitrocellulose, and subjected to Western blot analysis with anti-SpoVG anti-
bodies.
RESULTS AND DISCUSSION
Transcriptional control of the yabJ-spoVG locus. The B-
dependent yabJ-spoVG operon is transcribed as a bicistronic
mRNA, with smaller yabJ- and spoVG-specific bands appearing
later in growth and peaking toward early stationary phase (27).
To search for a potential transcriptional start point (TSP) for
the smaller spoVG transcript, we performed a primer extension
analysis and included the recently characterized yabJ promoter
(PyabJ) as a positive control (3, 18). This analysis confirmed the
TSP of the bicistronic yabJ-spoVG transcript previously iden-
tified by S1 nuclease mapping at position 548659 of the S.
aureus COL genome (GenBank accession no. NC_002951),
144 bp upstream of the yabJ ORF. The TSP is preceded by a
perfectly conserved B consensus promoter sequence (GTTT
AA-14-GGGTAT) (Fig. 2). A second potential TSP candidate,
at position 549247 of the S. aureus COL genome, that mapped
only 8 bp upstream of the spoVG ORF and immediately down-
stream of the proposed ribosomal binding site (Fig. 2C) was
identified. However, the sequence preceding the spoVG TSP
candidate shared no homology with either a A consensus
promoter (TTGACA-16/18-TATAAT) (10, 35) or a 
B consen-
sus promoter (GTTTAA-12/15-GGGTAT) (18), suggesting that
the small spoVG transcript may possibly be a result of process-
ing and not a product of a specific promoter.
To verify a putative promoter function suggested by the
signal preceding the spoVG ORF and to measure the activities
of the yabJ promoter and the candidate spoVG promoter, we
constructed a series of promoter-luc reporter gene plasmids
covering different parts of the yabJ-spoVG locus (Fig. 3A) and
introduced them into strain Newman and its rsbUVW-sigB
derivative, strain IK184. Plasmid pSTM19, whose sequence
covers the region preceding the spoVG ORF up to the yabJ
promoter region, as well as plasmid pSTM20, whose sequence
covers the yabJ upstream region, including PyabJ, produced, as
expected, comparable and high levels of luciferase activity in
strain Newman after 8 h of growth (Fig. 3B). However, plasmid
FIG. 2. Determination of TSP candidates of the yabJ-spoVG locus
of S. aureus by primer extension analysis. (A) Map of the yabJ-spoVG
region showing the positions of the two putative TSPs obtained with
primers yabJ-pe (diamond) and spoVG-pe (circle). Proposed ORFs,
promoters, and terminators are indicated. (B) Primer extension prod-
ucts (PEP) were analyzed on DNA sequencing gels together with GA
(lane A) and TC (lane T) sequencing ladders. Horizontal arrows
indicate the positions of the primer extension products. (C) Nucleotide
sequences of the putative S. aureus yabJ-spoVG operon promoters.
Vertical arrows indicate the nucleotides corresponding to the putative
TSPs. The predicted 35 and 10 promoter boxes are shown, and the
ribosomal binding site is underlined.
FIG. 3. yabJ-spoVG promoter activity. (A) Schematic representa-
tion of the yabJ-spoVG locus of S. aureus and of the reporter gene
plasmids pSTM19, pSTM20, and pSTM21 showing the portion of the
yabJ-spoVG region fused to the luciferase gene (luc). ORFs, promot-
ers, and terminators are indicated. (B) Luciferase activities of plasmids
pSTM19, pSTM20, and pSTM21 in strains Newman and IK184 (New-
man rsbUVW-sigB). The strains were grown in LB broth supple-
mented with 10 g ml1 tetracycline at 37°C and 180 rpm and were
sampled after 5 h of growth. The values represent the means  stan-
dard deviations from three independent assays.
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pSTM21, which harbors the 3 part of yabJ, including the pu-
tative spoVG TSP and the spoVG ATG but which lacks PyabJ,
yielded no luciferase activity, signaling that this region indeed
does not likely harbor a promoter. The two smaller bands
appearing in later growth stages are therefore degradation
products of the bicistronic yabJ-spoVG transcript. No luciferase
activities were found in IK184 transformed with either of the
plasmids, confirming the B dependence of the yabJ-spoVG
transcripts.
Influence of yabJ-spoVG on capsule formation in strain New-
man. Deletion of spoVG abolishes yabJ-spoVG transcription
and CP-5 production in strain Newman, as shown earlier (27).
In order to determine whether yabJ or spoVG was responsible
for capsule production, we substituted the complete operon
with an erm(B) cassette to be able to complement the resulting
yabJ-spoVG mutant, strain SM148, with a series of recombi-
nant plasmids harboring different parts of the yabJ-spoVG
operon (Fig. 4A). Confirming our earlier findings, the SM148
mutant produced no capsule after 8 h of growth (Fig. 4B). The
capsule could be restored by trans complementation with plas-
mid pSTM08 harboring yabJ-spoVG but not with plasmids car-
rying either yabJ (pSTM11) or spoVG (pSTM13) alone. From
these findings, we hypothesized that the yabJ-spoVG mRNA or
both products of the operon may be required for CP-5 forma-
tion. To test this hypothesis, we introduced a frameshift mu-
tation in either yabJ [yabJ1(Am)-spoVG] or spoVG [yabJ-
spoVG1(Am)], thereby maintaining the bicistronic transcript
but truncating and inactivating either YabJ or SpoVG. Inter-
estingly, the trans complementation of SM148 restored the
capsule only with the yabJ1(Am)-spoVG construct, pSTM10,
but not with the yabJ-spoVG1(Am) construct, pSTM09 (Fig.
4B). Western blots showed that only the complementing plas-
mids pSTM08 (yabJ-spoVG) and pSTM10 [yabJ1(Am)-spoVG]
produced SpoVG; but pSTM09 [yabJ-spoVG1(Am)], pSTM11
(yabJ), and pSTM13 (spoVG) did not (Fig. 4C), even though
they produced abundant amounts of mRNA (data not shown).
The apparent inability of the PyabJ-spoVG fusion (pSTM13) to
produce the SpoVG protein, despite the presence of spoVG
transcripts, may have been caused by a 2-nucleotide exchange
between the ribosomal binding site and the spoVG start codon
due to the cloning strategy. However, a PyabJ-spoVG fusion
construct with a restored wild-type sequence, as well as fusions
of spoVG, including its own ribosomal binding site to PyabJ,
failed to produce SpoVG (B. Schulthess, unpublished results),
suggesting a complex regulation of SpoVG translation that
FIG. 4. trans complementation of capsule production of SM148
(Newman yabJ-spoVG). (A) Schematic representation of the comple-
mentation plasmids. ORFs, promoters, and terminators are indicated.
(B) CP-5 expression determined by indirect immunofluorescence of
strain SM148 transformed with either pSTM08, pSTM09, pSTM10,
pSTM11, pSTM13, or empty control plasmid pBus1 grown in LB broth
for 8 h at 37°C. The CP-5 expression of strain Newman containing
pBus1 served as a control for wild-type CP-5 production. Bacteria were
stained with 4,6-diamidino-2-phenylindole (DAPI), marked with CP-
5-specific monoclonal antibodies, and stained with Cy-3-conjugated
antimouse antibodies (CY-3). (C) Western blot analysis of SpoVG in
cytoplasmic protein fractions of strain Newman and strain SM148
complemented with either pBus1, pSTM08, pSTM09, pSTM10,
pSTM11, or pSTM13 after 5 h of growth in LB broth.
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requires further investigations. Selective translation of the cod-
ing mRNA may have various causes, as reviewed by Gualerzi et
al. (14), for the translational control of cold shock genes, which
may also apply for the yabJ-spoVG operon. This suggests that
SpoVG is required for CP-5 production in strain Newman and
that the yabJ-spoVG mRNA but not YabJ is necessary for
SpoVG production and activity.
Influence of yabJ-spoVG on levels of antibiotic resistance in
MRSA and GISA. The activity of the alternative B factor
positively influences the levels of oxacillin and glycopeptide
resistance in MRSA and GISA strains (2, 28, 34, 39, 40).
However, the genes by which B affects the resistance levels
are not yet known. To see if the effect of B on resistance was
mediated by the yabJ-spoVG locus, we inactivated yabJ-spoVG
in MRSA strain COL and its plasmid-cured derivative, strain
COLn, and in GISA strains BB938 and NM143 by transduction
of yabJ-spoVG::ermB, yielding strains SM154, SM165, SM159,
and SM233. The levels of resistance of these four transductants
to oxacillin and teicoplanin, respectively were significantly re-
duced in a characteristic, strain-specific fashion, as shown by
population analysis profiles (Fig. 5), although the difference in
absolute MICs may be of debatable clinical relevance (Table
3). The MICs of the yabJ-spoVG mutant were comparable to
those of the corresponding rsbUVW-sigB mutants. Interest-
ingly, the reduction in the level of resistance to teicoplanin was
more pronounced than that to vancomycin. This may point to
an altered interaction of the lipophilic teicoplanin anchor with
FIG. 5. Antibiotic susceptibilities of MRSA strains COL (A) and
COLn (B) and GISA strains BB938 (C) and NM143 (D) and their
isogenic yabJ-spoVG mutants. Population analysis profiles for oxacil-
lin and teicoplanin, respectively are shown for each wild type (squares)
and the corresponding yabJ-spoVG mutant (triangles).
FIG. 6. trans complementation of oxacillin and teicoplanin resis-
tance. The yabJ-spoVG mutants SM165 and SM159 were comple-
mented with either pBus1 (empty plasmid), pSTM08 (yabJ-spoVG),
pSTM09 [yabJ-spoVG1(Am)], pSTM10 [yabJ1(Am)-spoVG], pSTM11
(yabJ), or pSTM13 (spoVG); and their levels of resistance were com-
pared with those of their corresponding wild-type strains, strains
COLn and BB938, respectively, on gradient plates containing oxacillin
(A) or teicoplanin (B).
TABLE 3. MICs
Strain
MIC (g ml1)
Oxacillin Teicoplanin Vancomycin
COL  256 NDa ND
SM154 128 ND ND
IK183 256 ND ND
COLn  256 ND ND
SM165  256 ND ND
BS128  256 ND ND
BB938 ND 24 6
SM159 ND 8 4
PG223 ND 8 4
NM143 ND 12 6
SM233 ND 6 6
BS126 ND 4 6
a ND, not determined.
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the membrane, while vancomycin, whose activity is enhanced
by dimerization, was apparently less affected.
Since strain COL harbors the tetracycline resistance plasmid
pT181, which interferes with our complementing plasmids, the
cured plasmid-less strain COLn was used for the trans comple-
mentation assays. Surprisingly, COLn had a higher level of
oxacillin resistance than COL, and the COLn yabJ-spoVG
mutant (strain SM165) had a smaller effect on oxacillin resis-
tance (Fig. 5A and B) that was, however, sufficient for visual-
ization on gradient plates and performance of trans comple-
mentation assays (Fig. 6). Similar to what was observed for
CP-5 formation, the trans complementation of oxacillin resis-
tance in SM165 and of teicoplanin resistance in SM159 was
successful only with plasmids pSTM08 and pSTM10, which
contained yabJ-spoVG and yabJ1(Am)-spoVG, respectively.
Plasmids pSTM11, pSTM13, and pSTM09 as well as the empty
plasmid, pBus1, had no effect, demonstrating that neither yabJ,
spoVG, nor yabJ-spoVG1(Am) was able to complement the
resistance.
This study showed that the deletion of the B-dependent
yabJ-spoVG operon in MRSA and GISA strains decreased the
resistance levels in a way similar to that found for the deletion
of B, suggesting that B exerts its effect on methicillin and
glycopeptide resistance via the gene products of the yabJ-
spoVG locus, in particular, via SpoVG. Which of the multiple
chromosomal genes affecting either methicillin or glycopeptide
intermediate resistance levels are controlled by the B-SpoVG
cascade remains to be identified.
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